Miraculins Passes ISO Certification Audit | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins today said that it has successfully completed a two-part ISO certification audit conducted by the BSI Group.

The Winnipeg, Manitoba-based biomarker-based diagnostics firm said that the audit recommended that the firm receive ISO 13485 certification. The company said the certification is a "critical regulatory and business plan milestone" as heads toward commercial launch of its PreVu Non-Invasive Skin Cholesterol test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.